BUSINESS

Ivermectin Shows Antiviral Effects against Omicron: Kowa

February 1, 2022
Kowa said on January 31 that the antiparasitic agent ivermectin, which the company is developing for the treatment of COVID-19, has shown antiviral effects against the Omicron variant of the novel coronavirus in in-vitro testing. According to the company, its…

To read the full story

Related Article

BUSINESS

By Sakura Kono

Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…

By Eric Persoff

President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…

By Tatsuya Otsuka

Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…